

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PRIMA BIOMED LIMITED	(ASX:PRR)
ABN	90 009 237 889	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Marc Voigt
Date of last notice	7 January 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct																								
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A																								
Date of change	5 August 2015																								
No. of securities held prior to change	<p>1) Ordinary Fully Paid Shares</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;">Shares</th> <th style="text-align: center;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: right;">870,000</td> <td style="text-align: right;">1,171,754</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: right;">870,000</td> <td style="text-align: right;">1,171,754</td> </tr> </tbody> </table> <p>2) American Depositary Receipts (ADR)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;">Shares</th> <th style="text-align: center;">Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">150</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">150</td> <td style="text-align: center;">-</td> </tr> </tbody> </table> <p>3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.</p>		Shares	Options	Direct	870,000	1,171,754	Indirect	-	-	Total	870,000	1,171,754		Shares	Options	Direct	150	-	Indirect	-	-	Total	150	-
	Shares	Options																							
Direct	870,000	1,171,754																							
Indirect	-	-																							
Total	870,000	1,171,754																							
	Shares	Options																							
Direct	150	-																							
Indirect	-	-																							
Total	150	-																							

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	Ordinary Fully Paid Shares																								
Number acquired	<p>1) Ordinary Fully Paid Shares</p> <table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>6,666,666</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>6,666,666</td> <td>-</td> </tr> </tbody> </table> <p>2) 20,000,000 Performance Rights</p>		Shares	Options	Direct	6,666,666	-	Indirect	-	-	Total	6,666,666	-												
	Shares	Options																							
Direct	6,666,666	-																							
Indirect	-	-																							
Total	6,666,666	-																							
Number disposed	6,666,666 Performance Rights																								
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<p>Nil</p> <p>The Performance Rights were issued for a range of remuneration and incentive purposes in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015. No amount is payable upon exercise of the Performance Rights for shares after vesting.</p>																								
No. of securities held after change	<p>1) Ordinary Fully Paid Shares</p> <table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>7,536,666</td> <td>1,171,754</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>7,536,666</td> <td>1,171,754</td> </tr> </tbody> </table> <p>2) American Depositary Receipts (ADR)</p> <table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td>150</td> <td>-</td> </tr> <tr> <td>Indirect</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>150</td> <td>-</td> </tr> </tbody> </table> <p>3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.</p> <p>4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015.</p>		Shares	Options	Direct	7,536,666	1,171,754	Indirect	-	-	Total	7,536,666	1,171,754		Shares	Options	Direct	150	-	Indirect	-	-	Total	150	-
	Shares	Options																							
Direct	7,536,666	1,171,754																							
Indirect	-	-																							
Total	7,536,666	1,171,754																							
	Shares	Options																							
Direct	150	-																							
Indirect	-	-																							
Total	150	-																							

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<ol style="list-style-type: none"> 1) 20,000,000 Performance Rights were issued in accordance with shareholder's approval obtained at the Extraordinary General Meeting on 31 July 2015. The first tranche of 6,666,666 vested immediately upon approval. After vesting of the first tranche, 13,333,334 Performance Rights remain to be vested subject to Mr Voigt meeting his service conditions over 2 subsequent annual tranches. 2) Acquiring 6,666,666 shares upon exercise of the first tranche of performance rights. One ordinary fully paid share was acquired for each Performance Right that vested.
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

05.08.2015

For personal use only

⁺ See chapter 19 for defined terms.